{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458460406
| IUPAC_name = ''N''-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-''N'''-methyl-2-nitroethene-1,1-diamine
| image = Ranitidine.svg
| width = 250
| image2 = File:Ranitidine-A-3D-balls.png

<!--Clinical data-->
| pronounce = {{IPAc-en|r|ə|ˈ|n|ɪ|t|ᵻ|d|iː|n}}
| tradename = Zantac, others
| Drugs.com = {{drugs.com|monograph|ranitidine-hydrochloride}}
| MedlinePlus = a601106
| licence_US = Ranitidine
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = S2
| legal_US = OTC
| legal_US_comment = /&nbsp;Rx-only
| legal_UK = GSL
| routes_of_administration = [[경구 투여]], [[정맥 주사]]

<!--Pharmacokinetic data-->
| bioavailability = 50% (경구)<ref name="AHFS2015">{{웹 인용|title=Ranitidine|url=https://www.drugs.com/monograph/ranitidine-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 1, 2015|url-status=live|archiveurl=https://web.archive.org/web/20170909005129/https://www.drugs.com/monograph/ranitidine-hydrochloride.html|archivedate=2017-09-09|df=}}</ref>
| protein_bound = 15%
| metabolism = [[간]]: [[FMO3]]를 포함한 [[플라빈 함유 모노옥시제네이스|FMOs]]과 그 외 효소
| elimination_half-life = 2~3시간
| excretion = 30–70% [[콩팥]]
| onset = 55~65분 (투여량 150mg)<ref name="pmid12144582" /><br />55~115분 (투여량 75mg)<ref name="pmid12144582">{{저널 인용| vauthors = Gardner JD, Ciociola AA, Robinson M, McIsaac RL | title = Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity | journal = Aliment. Pharmacol. Ther. | volume = 16 | issue = 7 | pages = 1317–1326 | date = July 2002 | pmid = 12144582 | doi = 10.1046/j.1365-2036.2002.01291.x | url = }}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66357-35-5
| ATC_prefix = A02
| ATC_suffix = BA02
| ATC_supplemental = <br />{{ATC|A02BA|07}} (ranitidine bismuth citrate)
| IUPHAR_ligand = 1234
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00863
| PubChem = 3001055
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4863
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 884KT10YB7
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00422
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 8776
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1790041
| synonyms = Dimethyl [(5-<nowiki/>{[(2-<nowiki/>{[1-(methylamino)-<br />2-nitroethenyl]amino}ethyl)sulfanyl]<br />methyl}furan-2-yl)methyl]amine

<!--Chemical data-->
| C=13 | H=22 | N=4 | O=3 | S=1
| molecular_weight = 314.4 g/mol
| smiles = [O-][N+](=O)C=C(NC)NCCSCc1ccc(o1)CN(C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VMXUWOKSQNHOCA-UHFFFAOYSA-N
}}
'''라니티딘'''(Ranitidine)은 [[H2 수용체 차단제]]로 작용하는 약물로 위내 산 생성작용을 억제한다. 주로 [[위궤양]]이나 [[역류성 식도염]] 치료에 사용된다. [[글락소스미스클라인]]의 잔탁(Zantac)이라는 상표명으로 자주 유통된다.

== 같이 보기 ==
* [[시메티딘]](Cimetidine)

== 각주 ==
{{각주}}

== 외부 링크 ==
* [https://web.archive.org/web/20170821045645/http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/ 라니티딘]

{{토막글|의학}}

[[분류:H2 수용체 길항제]]
[[분류:퓨란]]
[[분류:싸이오에터]]
[[분류:간독소]]
[[분류:글락소스미스클라인의 제품]]
[[분류:노바티스의 제품]]
[[분류:세계 보건 기구 필수 의약품]]
[[분류:콩팥 독소]]
[[분류:시장에서 철퇴된 약]]